Skip to main content

Cutaneous Lupus Erythematosus Landscape: Pathophysiology, Unmet Needs, and Related Challenges in Clinical Practice. What is on the Horizon?

120kviews
Editorial27 February 2024
Editorial: Cutaneous lupus erythematosus landscape: pathophysiology, unmet needs, and related challenges in clinical practice. What is on the horizon?
Joseph F. Merola, Filippa Nyberg, Nathalie Franchimont, Catherine Barbeyand Victoria P. Werth

Investigation of the incidence and prevalence of CLE in the absence of systemic lupus erythematosus (SLE) has been limited to date (1). Current epidemiological studies suggest that race and ethnicity do affect CLE diagnosis frequency: discoid lupus erythematosus (DLE) occurs more frequently in Black or Hispanic patients and subacute cutaneous lupus erythematosus (SCLE) occurs more frequently in White populations. Both the severity and disease course can differ by race for CLE. For instance, black patients have been shown to have higher baseline disease damage (as measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) instrument) than non-Black patients, and strong correlation was found between CLASI-damage and activity score in black while there were no correlation in white patients. Disease activity has been shown to impact Quality of Life (QoL) (2). Additionally, sociodemographic factors contribute to overall outcomes in CLE patients with income, educational background, and access to health insurance among the contributing factors. Additional epidemiological data and analyses of CLE disease burden across race and ethnicity are needed and diversity inclusiveness is warranted in CLE studies (1).The pathophysiology of CLE resembles and overlaps with that of SLE. Many factors have been proposed to trigger immune responses in CLE including genetic predisposition, environmental factors such as ultraviolet irradiation, and certain pharmaceutical agents (3)(4)(5). Multiple genes responsible for mediating innate immune response, cell growth, apoptosis, and interferon response as well as increased frequency of HLA-B8 and C2 complement deficiency have been identified as genetic aberrations or transcript anomalies linked to CLE (3). Numerous mechanisms driven by ultraviolet light have been identified to contribute to the pathogenesis of CLE (4). These mechanisms result in the chronic activation of immune pathways, which is considered a hallmark mechanism of CLE pathophysiology and is characterized by the production of type I interferon (IFN-I) (5). CLE has three major subtypes: SCLE, acute (ACLE), , and chronic (CCLE), and patients may exhibit more than one subtype at a time (6). Elmgren & Nyberg reviewed the association of CLE with SLE noting that while many shared features point to CLE and SLE as being part of a disease spectrum, current evidence suggests that they are closely related but distinct diseases with different courses (6). Histopathologically, CLE is characterized by the presence of lymphocytic infiltrates and necroptotic keratinocytes at the dermo-epidermal junction. However, CLE subtypes are heterogeneous in their clinical appearance, and histopathological features. Fetter et al summarize the histopathological features characteristic of the different CLE subtypes in their review, acknowledging that the overlap in histology often does not allow a clinical subset diagnosis from histology and highlights the importance of knowing the specific subtype molecular signature to develop a precision medicine approach to CLE treatment (5).There are no drugs approved specifically for the treatment of CLE to date. Current treatment guidelines for CLE recommend a combination of preventive measures and topical and systemic medications (7). First-line treatment may include topical corticosteroids and systemic antimalarials Second-and third-line systemic treatments include immunosuppressants and immunomodulatory drugs. Targeted biologics approved for the treatment of SLE may be available to the subset of patients with CLE Despite recommended treatment guidelines, approximately 10% of CLE patients have been shown to be refractory to therapy (8). As such, there is a clear need to develop targeted therapies specifically for CLE.Development of novel CLE specific therapies is currently a growing area, but is complicated by the lack of standardized outcome measures to be used in clinical trials. Gaffney, Werth, & Merola summarize a working core domain set and core outcome set for CLE recommended for use in clinical trials as an interim guide until standardized outcomes are fully available (9)(10). The authors discussed currently available and new clinical outcomes, such as the CLASI scale and/or a CLE-specific investigator global assessment of disease activity (CLA-IGA). They also reviewed patient reported outcomes, and QoL measures such as the Skindex-29+3 and the CLE-QoL. Not all of these outcome measures have been validated in CLE highlighting future requirements for additional work in this area (9).Although no therapies have been approved specifically for the treatment of CLE, several emerging therapies are under investigation (11). Although anifrolumab and belimumab were previously not studied in CLE specific trials, analyses of skin focused outcome measures of SLE patients with skin manifestations showed improvement in the treatment groups over placebo suggesting promise of these agents for CLE. CLE specific studies are currently underway with agents targeting various pathways such as the IFN-alpha receptor (anifrolumab), plasmacytoid dendritic cell (litifilimab () and daxdilimab ()), TYK-2 (deucravacitinib), toll-like receptor (enpatoran (), and interleukin-1 receptor-associated kinase 4 (IRAK4) (edecesertib). Litifilimab and daxdilimab have previously demonstrated clinical benefit in some forms of CLE but need to be investigated in larger and longer trials (12)(13).Patients living with CLE experience poor QoL, particularly in the psychological and social health domains (14). Many factors have been reported to negatively impact health-related QoL (HRQoL) for CLE patients including female sex, low education, and higher skin disease activity among others. Pain, fatigue, disease activity, body image, and medication side effects are specific areas that CLE patients have reported impacting their QoL. With regards to the psychological domain, CLE patients have an increased prevalence of major depressive disorder, generalized anxiety disorder, panic disorder, suicide risk, and agoraphobia. Altogether, these observations highlight the need to provide new therapeutic solutions for CLE patients that would improve their quality of life.The current landscape of CLE presents many areas of opportunity for the scientific and healthcare community to pursue including improving diagnoses, identifying and understanding the molecular mechanisms driving disease, developing novel therapies to target these mechanisms. These endeavours should be considered in a patient-centric approach to ultimately improve patient outcomes and quality of life for those living with CLE.

3,780 views

3 citations

Lupus erythematosus (LE) is an autoimmune inflammatory disease with a wide clinical spectrum from life-threatening multi-organ inflammation in systemic lupus erythematosus (SLE) to limited skin disease in cutaneous LE (CLE). The etiology of CLE is still not fully understood but a multifactorial genesis with genetic predisposition and certain environmental factors as triggers for the development are generally accepted features. Lesions can be induced and aggravated by UV-irradiation and smoking is linked to more severe forms of skin disease and to co-morbidity. Drugs, including many common medicines like antihypertensives, are known to induce subacute CLE (SCLE). The mechanisms involved have recently been shown to be part of the IFN-I pathway and new, specific treatments are currently in clinical trials. CLE is currently classified in subtypes based on clinical presentation and duration into acute CLE (ACLE), SCLE and chronic CLE (CCLE). Distinct subtypes can be seen in individual patients or coexist within the same patient. Because of the confluent and overlapping picture between these subsets, serology, and histopathology constitute an important role guiding towards correct diagnose and there is ongoing work to update the classification. The Cutaneous Lupus Area Severity Index (CLASI) is a validated tool to measure activity and damage both in clinical trials but also for the clinician to evaluate treatment and follow the course of the disease among patients. CLE is known to have substantial impact on the life of those affected. Several tools have been proposed to measure QoL in these patients, currently Skindex-29 is probably the most used. Patient education is an important part of prevention of flares, including UV-protection and smoking cessation. First-line treatment includes topical corticosteroids as well as topical calcineurin inhibitors with the addition of systemic treatment with antimalarials in more severe or therapy resistant cases. Treatment specifically targeting CLE has been lacking, however novel potential therapies are in later phase clinical trials. In this review we aim to describe the different subsets of the cutaneous form in LE with focus on clinical aspects.

16,966 views

27 citations

Cutaneous lupus erythematosus (CLE) is a group of heterogeneous autoimmune disorders primarily affecting the skin. Patients with these conditions are mostly young women when they become sick and often suffer from recurrent skin symptoms or longstanding changes in their physical appearance. CLE disorders lead to different levels of morbidity and can impact profoundly patients’ quality of life, particularly in the psychological and social health domains. This review provides a summary of recent research investigating the psychosocial burden of living with CLE and the intersect amongst the disease characteristics, patient factors, and social determinants of health. Furthermore, this review provides insight into patient care and research needs that remain unmet to improve the quality of life of patients living with CLE.

7,855 views

17 citations

4,361 views

14 citations

Cutaneous lupus erythematosus (CLE) is an autoimmune disease that can occur with or without underlying systemic lupus erythematosus (SLE) and often has a profoundly negative impact on patient quality of life. There is substantial need for new and more effective therapies to treat CLE. CLE has a multifactorial pathogenesis that involves several key immune cells and pathways, including abnormalities in innate (e.g., type 1 interferon pathways) and adaptive immune responses (e.g., B and T cell autoreactivity), presenting multiple opportunities for more targeted therapies that do not require immunosuppression. Here we review several emerging therapies and their efficacy in CLE. Anifrolumab and belimumab have both been approved for the treatment of SLE in recent years, and clinical trial evidence suggests some forms of CLE may improve with these agents. Therapies currently in development that are being evaluated with CLE-specific outcome measures include BIIB059 and VIB7734, which target plasmacytoid dendritic cells (pDCs), and iberdomide, a cereblon modulator. These novel therapies all have previously demonstrated clinical benefit in some forms of CLE. Other therapies which target molecules believed to play a role in CLE pathogenesis, such as janus kinases (JAKs), spleen tyrosine kinase (SYK), interferon γ (IFNγ), IL-12, and IL-23, have been evaluated in lupus clinical trials with skin-specific outcomes but failed to meet their primary endpoints.

9,085 views

12 citations